| Project/Area Number |
16K15645
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TERASAKI Tetsuya 東北大学, 薬学部, 教授 (60155463)
OHTSUKI Sumio 熊本大学, 薬学部, 教授 (60323036)
|
|---|
| Research Collaborator |
SHUKURU Hemurasabit 金沢大学, 医学系, 博士研究員 (10432113)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | バイオマーカー / 膠芽腫 / プロテオミクス |
|---|
| Outline of Final Research Achievements |
Reliable blood biomarkers could be helpful for the management of glioblastoma (GBM) patients. Mass spectrometry (MS)-based proteomic analysis of human clinical blood is a powerful tool to investigate cancer biomarkers. To identify the biomarkers for GBM, we applied the highly accurate and reproducible SWATH (Sequential Windowed Acquisition of all Theoretical fragment ions)-MS technique. Quantitative comparisons of the plasma proteomes of GBM, IDH-wildtype patients (n = 14) and healthy controls (n = 15) were performed. Data dependent analysis mode of LC-MS/MS (Liquid chromatography tandem-MS) detected total 962 species of proteins in the samples used. Through the SWATH analysis, we identified five biomarker candidates for GBM: up-regulated proteins; α-1-antichymotrypsin (SERPINA3), and complement component C9 (C9), down-regulated proteins; gelsolin (GSN), Ig α-1 chain C region (IGHA1), and apolipoprotein A-IV (APOA4).
|
